Amneal Pharmaceuticals has just seen its fair value estimate nudged to US$14.00 from US$13.80, a small but meaningful reset that ties directly to how the latest quarterly numbers stack up against ...

According to IQVIA ® U.S. annual sales for epinephrine injection single- and multi-dose vials for the 12 months ended October 2025 were approximately $118 million.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. Glenmark's Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) ...

Glenmark Pharmaceuticals said that its wholly owned subsidiary, Glenmark Pharmaceuticals Inc., USA, has announced the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial in ...

Glenmark Pharma launches epinephrine injection USP in US market: Our Bureau, Mumbai Tuesday, December 23, 2025, 14:15 Hrs [IST] Glenmark Pharmaceuticals Inc., USA (Glenmark) annou ...

The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.

BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Investing.com -- Amneal Pharmaceuticals Inc Class A (NASDAQ:AMRX) stock rose 2.8% in after-hours trading Tuesday following the FDA approval of the company’s epinephrine injection USP, expanding its ...

BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced Tuesday that the U.S. Food and Drug Administration has approved its epinephrine injection USP in both single-dose and ...